![](/img/cover-not-exists.png)
PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS
J Huels, A Wright, K Kahler, M Omar, RW Dubois, CF Chiou, OV DoanVolume:
9
Year:
2006
Language:
english
DOI:
10.1016/s1098-3015(10)64387-2
File:
PDF, 79 KB
english, 2006